Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.

doi:10.1016/j.lungcan.2020.04.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2020

Scheffler Matthias, Holzem Alessandra, Kron Anna, Nogova Lucia, Ihle Michaela A, von Levetzow Cornelia, Fassunke Jana, Wömpner Claudia, Bitter Elisabeth, Koleczko Sophia, Abdulla Diana S Y, Michels Sebastian, Fischer Rieke, Riedel Richard, Weber Jan-Philipp, Westphal Theresa, Gerigk Ulrich, Kern Jens, Kaminsky Britta, Randerath Winfried, Kambartel Karl-Otto, Merkelbach-Bruse Sabine, Büttner Reinhard, Wolf Jürgen

Abstract excerpt

BACKGROUND: MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive from known driver mutations. Activation of the MEK1-cascade is considered pivotal in resistance to targeted therapy approaches, and MAP2K1 K57 N mutation could be linked to resistance in preclinical models. We set out this study to detect MAP2K1 mutations and potentially targetable co-mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kelch-Like ECH-Associated Protein 1

Share to Lung Neoplasms

Share to MAP Kinase Kinase 1

Share to Mutation

Share to NF-E2-Related Factor 2

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed

Identifiers

PMID: 32361034
DOI: 10.1016/j.lungcan.2020.04.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.PMID 32361034Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective AnalysisSemantic proximity Read ↗

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.Semantic proximity Read ↗

Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective StudySemantic proximity Read ↗

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Semantic proximity Read ↗

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysSemantic proximity Read ↗

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.